Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-407-9 | CAS number: 2144-53-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The test substance is rapidly metabolised in vitro in mammalian and trout hepatocytes, as well as in vivo in rats. Predicted BCF for the test substance indicates that it would not bioaccumulate in fish.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
In an in vivo biopersistence and pharmacokinetic study, rats were given 300 mg/kg orally in a single dose. Blood plasma, liver, and fat were collected at various time points from 0 to 168 hours, and were analysed for presence of the test substance. The test substance was detected in very small amounts in plasma (< 40.0 ng/mL at the 1-, 2- and 4-hour post-dosing time points), liver (< 20.0 ng/mL at the 6-, 12-, and 24-hour post-dosing time points), and fat (< 20.0 to 99.9 ng/g at the 6-, 12-, 24-, 48-, 72-, and 96-hour post-dosing time points).
Metabolism of the test substance was examined in male and female rat hepatocytes and male mouse hepatocytes compared to heat inactivated controls. The half-life in male and female rat hepatocytes was reported as <3 minutes, as an actual rate was not attainable due to the fact that there was <5% of the parent compound remaining 5 minutes after incubation and no parent compound remaining after 15 minutes of incubation. Significant metabolism was also observed in male mice hepatocytes, but half- life and clearance rates could not be calculated due to the shape of the data curve. The steep portion of the curve between 0 and 3 minutes indicated rapid metabolism (5 µM to 1.1 µM). In the in vitro rat and mouse hepatocyte study, the largest metabolite was 6:2 uFTOH-GH. Additional major metabolites in rat hepatocytes included 6:2 GTOH-Gluc, 6:2 diOH-diGluc, 6:2 FTOH (by GC/MS), 6:2 FMA-GS (male hepatocytes only), 6:2 FTOH-Sulf (female hepatocytes only), and 6:2 UAL-GS (isomer II DNPH deriv.) (female hepatocytes only). Additional major metabolites in mouse hepatocytes included 6:2 UA-GS, 6:2 uFTOH-N-acetyl-GS, 5:2 OH-Gluc, 6:2 FTOH-Gluc, and 5-2 Ketone (DNPH deriv.).
Metabolism of the test substance was also examined in freshly isolated trout hepatocytes. Time-dependent disappearance of the test substance was observed. The steep portion of the curve between 0 and 30 minutes indicates rapid metabolism, with 83% loss of the parent compound. The curve shape in the live incubations was biphasic, with a rapid elimination phase in the first 30 minutes (alpha phase) and a slower rate between 30 and 90 minutes (beta phase). The calculated trout hepatic clearance for the test substance was 112.7 mL/h/kg. Based on the findings of this study, the predicted BCF for the test substance is 268, indicating that it would not bioaccumulate in fish.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
